Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Novartis (Switzerland) · Novartis Institutes for BioMedical Research
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,250
total citations
- FWCI
- 33.89
- Percentile
- 100%
- References
- 156
Citations per year
Authors
8- VBVolker BrinkmannCorresponding
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- ABAndreas Billich
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- TBThomas Baumruker
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- PHPeter Heining
Novartis (Switzerland), Novartis Institutes for BioMedical Research
- RSRobert Schmouder
Topics & keywords
Topics
Keywords
- Fingolimod
- Multiple sclerosis
- Medicine
- Drug discovery
- Pharmacology
- Sphingosine
- Sphingosine-1-phosphate receptor
- Food and drug administration
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.